Statistics from Altmetric.com
What are the effects of the 12 most commonly prescribed new generation antidepressants for moderate to severe major depression in adults?
Response to treatment at 8 weeks, defined as the proportion of patients having a 50% or greater reduction from baseline in Hamilton Depression Rating Scale or Montgomery–Asberg depression rating scale or those scoring “much improved” or “very much improved” on the clinical global impression; discontinuation as a measure of acceptability of treatment defined as the number of patients who terminated the study early for any reason during the first 8 weeks of treatment.
Systematic review with meta-analysis (pairwise with random effects model and mixed treatment meta-analysis).
Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials registers (searched November 2007).
Study selection and analysis:
Randomised controlled trials comparing any of the following new generation antidepressants being used as monotherapy to treat adults with unipolar major depression: duloxetine, velanfaxine, sertraline, bupropion, citalopram, escitalopram, fluoxetine, minacipran, fluvoxamine, mirtazapine, paroxetine and reboxetine were included. Two independent reviewers evaluated the methodological quality of the trials and extracted the data. Responders to treatment were calculated on a conservative intention …
Sources of funding Unclear.
Competing interests: RHM-W has received support from a number of pharmaceutical companies who manufacture antidepressants, including Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, Pfizer, Servier and Wyeth.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.